Abstract
A randomized, double‐blind, placebo‐controlled clinical trial has shown that treatment of the common cold with zinc gluconate lozenges resulted in a significant reduction in duration of symptoms of the cold. Patients received zinc‐containing lozenges or placebo lozenges every 2 hours for the duration of cold symptoms. The median time to complete resolution of cold symptoms was 4.4 days in the zinc group compared with 7.6 days in the placebo group. The mechanism of action of zinc in treating the common cold remains unknown.
References
- 1. Mossad S, Macknin M, Medendorp S, Mason P. Zinc gluconate lozenges for treating the common cold: a randomized, double‐blind, placebo‐controlled study. Ann Intern Med 1996;125:81–8. [DOI] [PubMed] [Google Scholar]
- 2. Eby G, Davis D, Halcomb W. Reduction in duration of the common cold by zinc gluconate lozenges in a double‐blind study. Antimicrob Agents Chemother 1984;25:20–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Al‐Nakib W, Higgins P, Barrow I, et al. Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. J Antimicrob Chemother 1987;20:893–901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Godfrey J, Conant Sloane B, Smith D, et al. Zinc gluconate and the common cold: a controlled clinical study. J Int Med Res 1992;20:234–46. [DOI] [PubMed] [Google Scholar]
- 5. Farr B, Conner E, Betts R, et al. Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. Antimicrob Agents Chemother 1987;31:1183–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Douglas R, Miles H, Moore B, et al. Failure of effervescent zinc acetate lozenges to alter the course of upper respiratory tract infections. Antimicrob Agents Chemother 1987;31:1263–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Smith D, Helzner E, Nuttall C, et al. Failure of zinc gluconate in treatment of acute upper respiratory tract infections. Antimicrob Agents Chemother 1989;33:646–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Weismann K, Jakobsen J, Weismann J, et al. Zinc gluconate lozenges for the common cold: a double‐blind clinical trial. Dan Med Bull 1990;37:279–81. [PubMed] [Google Scholar]
- 9. Godfrey J. Zinc for the common cold [letter]. Antimicrob Agents Chemother 1988;32:605–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Eby G. Stability constants of zinc complexes affect common cold treatment results [letter]. Antimicrob Agents Chemother 1988;32:606–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Zarembo J, Godfrey J, Godfrey N. Zinc (II) in saliva: determination of concentrations produced by different formulations of zinc gluconate lozenges containing common excipients. J Pharm Sci 1992;81:128–30. [DOI] [PubMed] [Google Scholar]
- 12. Hill GM, Brewer GJ, Juni JE, et al. Treatment of Wilson's disease with zinc. II. Validation of oral 64copper with copper balance. Am J Med Sci 1986; 292: 344–9. [DOI] [PubMed] [Google Scholar]
- 13. Chandra RK. Excess intake of zinc impairs immune function. JAMA 1984;252:1443–6. [PubMed] [Google Scholar]